Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says
Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says
Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says
Submitted by
admin
on September 28, 2017 - 6:28pm
Source:
Fierce Pharma
News Tags:
Novartis
radiotherapy
M&A
Advanced Accelerator Application
neuroendocrine
Headline:
Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says
Do Not Allow Advertisers to Use My Personal information
